AAV9 Rep-Cap plasmid (serotype 9 - specific AAV RC9 plasmids)
AAV serotype 9 (AAV capsid 9) system - Introduction
GeneMedi's AAV9 Rep-Cap plasmid (serotype 9-specific AAV RC plasmid), also named AAV9-RC plasmid, or AAV-RC9 plasmid, is part of AAV9 packaging system. AAV9 Rep-Cap plamid supplies the AAV9 Rep (replication) proteins and the AAV9 capsid protein.
You can produce AAV9 paticle in 293T cell line in high titer using GeneMedi's AAV9 Rep-Cap plasmid with GeneMedi's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV9 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.
Product Name | Organization Type | Price(In USD) | Qty (Quantity) | Sum(In USD) |
---|---|---|---|---|
AAV9 Rep-Cap Plasmid Cat.No.:P-RC13 Serotype: AAV9 Size: 5ug | Academic | 935 | ||
AAV9 Rep-Cap Plasmid Cat.No.:P-RC13 Serotype: AAV9 Size: 5ug | Industry R&D (excluding CRO&CDMO&CXO) | Inquiry | ||
AAV9 Rep-Cap Plasmid Cat.No.:P-RC13 Serotype: AAV9 Size: 5ug | CRO&CDMO& CXO&CMC& Manufacturing company | Inquiry | ||
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service. | ||||
Shipping Cost: | 169.00 | |||
Total: | ||||
AAV9 vector tissue tropism and gene transduction (serotype-specific AAV infection)
The tissue tropism of AAV9 vector has been validated in neuron(CNS), heart, muscle, retina and Pancreas, with potential applications in tissue-specific gene therapy.
Virus and titer: AAV9-GFP, AAV9-pTBG-Luciferase (AAV-Luc), 1.4×1012 vg/ml Animal: mouse, C57, 2 months Gene delivery method: tail vein, 100μl Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy, in vivo imaging Conclusion: intravenous injection of AAV9-pTBG-Luciferase (AAV-Luc) only infects liver cells and no non-specific infection
Virus and titer: AAV9-GFP, 1×1012 vg/ml Animal: Rat, SD, 2 months (Figure 8A, B, C); mouse, C57, 8 months (Figure 8D) Infection site: heart Gene delivery method: myocardial in situ injection, 10μl/site, 5 sites in total (Figure 8A, B, C);intraorbital intravenous injection (Figure 8D) Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV9-GFP, 1×1012 vg/ml Animal: Mouse, C57, 2 months Infection site: Brain Gene delivery method: Brain localization injection, 1μl Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV9-GFAP-GFP, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: Hippocampus Gene delivery method: Brain localization injection, 1μl Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy
Virus and titer: AAV9-Luciferase (AAV-Luc), AAV9-GFP, 1×1012 vg/ml Animal: Mouse, C57, 2 months Infection site: Skeletal muscles Gene delivery method: Muscle in situ injection, 10μl/site, 4 sites in total Determine assay: 4 weeks post infection, in vivo imaging, frozen section, immunofluorescence microscopy
Virus and titer: AAV-DJ-GFP, AAV9-GFP, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: Kidney Gene delivery method: Multiple sites injection in kidney 10μl/site, 6 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml Animal: Nude mouse, 2 months Infection site: Subcutaneous transplant of bowel cancer cells Gene delivery method: Tumor injection, 10μl/site, 4 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV9-GFP, 1×1012 vg/ml Animal: mouse, C57, 2 months Infection site: Mammary fat pad Gene delivery method: Breast injection, 10μl/site, 4 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×1012 vg/ml Animal: Nude mouse, 2 months Infection site: Subcutaneous transplant of bowel cancer cells Gene delivery method: Tumor injection, 10μl/site, 4 sites in total Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml Cells: HEK-293T MOI: MOI=1×104 Determine assay: 36 hours post infection, immunofluorescence microscopy
Other AAV Rep-Cap Plasmid